We are live on ! Find out more
AC

Armistice Capital Portfolio holdings

AUM $5.62B
1-Year Est. Return 36.06%
This Fund
S&P 500
This Quarter Est. Return
+5.44%
1 Year Est. Return
+36.06%
3 Year Est. Return
+44.14%
5 Year Est. Return
+38.37%
10 Year Est. Return
+188.88%
AUM
$5.59B
AUM Growth
+$1.23B
Cap. Flow
-$770M
Cap. Flow %
-13.79%
Top 10 Hldgs %
47.55%
Holding
148
New
37
Increased
36
Reduced
28
Closed
32

Top Buys

Rank Stock Value
1
IOVA icon
Iovance Biotherapeutics
IOVA
+$87.6M
2
BURL icon
Burlington
BURL
+$81.6M
3
TVTX icon
Travere Therapeutics
TVTX
+$66.9M
4
HAE icon
Haemonetics
HAE
+$44.2M
5
WSM icon
Williams-Sonoma
WSM
+$43.8M

Top Sells

Rank Stock Value
1
TJX icon
TJX Companies
TJX
+$74.6M
2
LNTH icon
Lantheus
LNTH
+$57.7M
3
AAP icon
Advance Auto Parts
AAP
+$50.2M
4
NKE icon
Nike
NKE
+$42.9M
5
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$40.6M

Sector Composition

Rank Sector Weight
1 Healthcare 43.79%
2 Consumer Discretionary 10.03%
3 Consumer Staples 7.94%
4 Communication Services 2.1%
5 Industrials 1.95%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
WMT icon
51
Walmart Inc
WMT
$885B
$30.8M 0.55%
654,783
-612,021
-48% -$28.5M
META icon
52
Meta Platforms (Facebook)
META
$1.42T
$29.2M 0.52%
+84,000
New +$26.9M
MDLZ icon
53
Mondelez International
MDLZ
$79.5B
$28.5M 0.51%
456,000
-80,000
-15% -$4.93M
BIOR
54
DELISTED
Biora Therapeutics, Inc. Common Stock
BIOR
$27.1M 0.49%
30,389
+19,899
+190% +$15.2M
NSTG
55
DELISTED
NanoString Technologies, Inc.
NSTG
$27M 0.48%
+416,000
New +$26.4M
SBUX icon
56
Starbucks
SBUX
$120B
$26.8M 0.48%
+240,000
New +$27.1M
KOF icon
57
Coca-Cola Femsa
KOF
$22.7B
$26M 0.47%
492,000
+56,000
+13% +$2.76M
MSFT icon
58
Microsoft
MSFT
$3.45T
$26M 0.47%
96,000
-12,000
-11% -$3.05M
CRSP icon
59
CRISPR Therapeutics
CRSP
$4.73B
$25.6M 0.46%
158,000
+2,000
+1% +$243K
NTRA icon
60
Natera
NTRA
$38.3B
$25.4M 0.46%
224,000
-24,000
-10% -$2.46M
DXCM icon
61
DexCom
DXCM
$31.5B
$24.8M 0.44%
232,000
-96,000
-29% -$9.22M
TTWO icon
62
Take-Two Interactive
TTWO
$45.4B
$24.1M 0.43%
+136,000
New +$24.1M
AXNX
63
DELISTED
Axonics, Inc. Common Stock
AXNX
$24M 0.43%
378,000
-40,000
-10% -$2.36M
MA icon
64
Mastercard
MA
$502B
$23.4M 0.42%
+64,000
New +$23.8M
URBN icon
65
Urban Outfitters
URBN
$6.35B
$23.2M 0.42%
+563,936
New +$21.3M
ILMN icon
66
Illumina
ILMN
$31B
$20.8M 0.37%
45,232
-4,112
-8% -$1.66M
ADMS
67
DELISTED
Adamas Pharmaceuticals
ADMS
$20.4M 0.36%
3,856,000
– –
AHCO icon
68
AdaptHealth
AHCO
$1.47B
$20.2M 0.36%
+736,000
New +$21M
NUVA
69
DELISTED
NuVasive, Inc.
NUVA
$20.1M 0.36%
296,000
-104,000
-26% -$7.1M
KMB icon
70
Kimberly-Clark
KMB
$36.3B
$19.8M 0.35%
+148,000
New +$19.7M
CL icon
71
Colgate-Palmolive
CL
$73.1B
$19.2M 0.34%
236,000
– –
KDNY
72
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$17.5M 0.31%
+1,236,000
New +$19.8M
DCPH
73
DELISTED
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
$17.3M 0.31%
+472,000
New +$18.3M
WYNN icon
74
Wynn Resorts
WYNN
$10.3B
$15.7M 0.28%
128,000
+64,000
+100% +$8.15M
VYGR icon
75
Voyager Therapeutics
VYGR
$183M
$15.3M 0.27%
3,716,000
– –
1 2
3
4 5

Similar funds

CRC
Curi RMB Capital Chicago, Illinois $5.62B AUM 18.93% 1-Year Est. Return
RMDI
R.M. Davis Inc Portland, Maine $5.63B AUM 21.26% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return
DCP
DSM Capital Partners Palm Beach Gardens, Florida $5.66B AUM 27.45% 1-Year Est. Return
EW
Evoke Wealth Los Angeles, California $5.57B AUM 23.85% 1-Year Est. Return
O
Ossiam Paris, France $5.69B AUM 30.95% 1-Year Est. Return
PA
Parallel Advisors San Francisco, California $5.56B AUM 17.89% 1-Year Est. Return
DSC
Donald Smith & Co New York $5.56B AUM 47.13% 1-Year Est. Return

Armistice Capital's Q2 2021 Portfolio in Review

As of Q2 2021, Armistice Capital held 148 positions worth $5.59B, up 28% from $4.36B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Armistice Capital withdrew a net $770M in Q2 2021, closing 32 positions and reducing 28 holdings. Its most notable exit was TJX Companies, an estimated $74.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 44% of assets, down from 47% a quarter earlier, followed by Consumer Discretionary and Consumer Staples.

Against the trend, Armistice Capital opened a new position in Iovance Biotherapeutics worth $87.7M.

  • Armistice Capital's largest Q2 2021 buy was Iovance Biotherapeutics: 3,372,000 shares worth $87.7M.
  • Armistice Capital added most to Travere Therapeutics in Q2 2021, an estimated $66.9M increase.
  • Armistice Capital's biggest Q2 2021 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $40.6M.
  • Armistice Capital fully exited TJX Companies in Q2 2021, selling an estimated $74.6M.
  • Armistice Capital's ten largest holdings make up 48% of its $5.59B portfolio in Q2 2021.
  • Armistice Capital opened 37 new positions and closed 32 in Q2 2021.
  • Armistice Capital's portfolio value rose 28% quarter-over-quarter to $5.59B.

Based on Armistice Capital's 13F filing for Q2 2021, filed 16 Aug 2021.